Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
November 25, 2020
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
November 24, 2020
Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 20, 2020
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2020
Revance to Participate in the Stifel 2020 Virtual Healthcare Conference
November 9, 2020
Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 9, 2020
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
November 3, 2020
Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference
November 2, 2020
Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020
October 23, 2020
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2020
Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Displaying 51 - 60 of 278